All In Biotech

Drug Trial Radar · NCT06368921

A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors

A Phase I Clinical Study to Evaluate the Safety, Tolerability, Biodistribution Characteristics, Biological Effects and Initial Efficacy of Recombinant Oncolytic Virus M1 for Injection (VRT106) in the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jun 19, 2024

Primary completion

Sep 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Apr 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To Evaluate the safety and tolerability of single and multiple intratumoral injections of recombinant oncolytic virus M1 (VRT106) in patients with locally advanced/metastatic solid tumors.

Conditions

  • Solid Tumor

Interventions

  • VRT106Biological

    intratumoral injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of escalating doses of intratumoral injection of VRT106.Time frame: About 2 years
  2. Characterize the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) levels.Time frame: About 2 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Affiliated Cancer Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Affiliated Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.